Virtual Investor Event
Autoimmune Deep Dive
Guillain-Barré Syndrome
Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.
28 April 2025, 14:00 CEST / 8:00 AM ET
Register and attend